Data presented as Late Breaking Trial at EuroPCR and published in Eurointervention show a single subcutaneous injection of RUC-4 consistently induced high-grade inhibition of platelet function

SAN DIEGO, May 18, 2021 – CeleCor Therapeutics, Inc. today announced the presentation of clinical trial results of RUC-4 in in patients experiencing a ST-segment Elevation Myocardial Infarction (STEMI). The data was presented in a Late Breaking Trial and published simultaneously in Eurointervention. The open-label, dose-escalating phase 2A clinical study (CEL-02) in 27 patients with ST-segment elevation myocardial infarction (STEMI) demonstrated a single subcutaneous dose of 0.110 mg/kg of zalunfiban (RUC-4), a second-generation glycoprotein IIb/IIIa inhibitor (GPI), consistently induced high-grade inhibition of platelet function within 15 minutes, with 50% of return of function at a median of 112 minutes. The study also did not observe thrombocytopenia with zalunfiban treatment. Different from current GPIs, zalunfiban locks the GPIIb/IIIa receptor in its inactive state and does not induce a major conformational change implicated in the development of thrombocytopenia. The company is currently conducting a pivotal clinical trial, called CELEBRATE, in more than 1,600 STEMI patients treated in ambulances.